ENVALITH
デンカ株式会社 logo

Denka Company Limited

4061・Prime Market・Chemicals

Official website
デンカ株式会社 logo
Denka Company Limited4061

Business

Denka Company Limited is a comprehensive specialty chemicals manufacturer founded in 1915, forming a group comprising 57 subsidiaries and 11 affiliated companies. Its business is organized into four segments: "Electronics & Advanced Products," "Life Innovation," "Elastomers & Infrastructure Solutions," and "Polymer Solutions." The company offers a wide range of products, including high-performance electronic materials for AI and power infrastructure applications (Spherical Silica / Spherical Alumina (Fused Silica-based Fillers), High-Reliability Heat Dissipation Plate "ALSINK", etc.), vaccines, diagnostic reagents, and cancer treatment formulations, as well as Chloroprene Rubber, Specialty Admixtures, styrene-based resins, and food packaging materials. Its main customers span the manufacturing, healthcare, construction, and infrastructure sectors both domestically and internationally. Denka is a global company with manufacturing and research facilities in Singapore, China, Vietnam, Thailand, Germany, and other locations.

Business Model

A vertically integrated model based on in-house manufacturing, supplying products through sales subsidiaries such as YK ACROSS and overseas manufacturing subsidiaries. The company invests ¥14,768 million in R&D expenses with 849 R&D personnel, developing high-value-added products through combined organic, inorganic, and bio technologies. While securing specialty earnings through advanced materials that address megatrends such as AI and power infrastructure, the commodity business is positioned as a cash cow, maximizing profitability across the overall portfolio.

Company Strengths

Spherical Silica / Spherical Alumina possess high technological superiority for semiconductor encapsulants and heat dissipation materials, achieving net sales of ¥104,430 million and operating income of ¥13,886 million (13.3% margin) in the Electronics & Advanced Products segment in FY2026 (ending March 2026). Next-generation high-performance spherical filler manufacturing equipment at the Omuta Plant has been completed, strengthening supply capacity.

Since successfully manufacturing domestically-produced Chloroprene Rubber in 1962, the company has maintained an integrated production system at the Omi Plant. Even after the temporary suspension of manufacturing equipment at U.S. subsidiary DPE, supply has continued from the domestic Omi Plant, and the company possesses a unique technology and production foundation aimed at maintaining its world-leading share. The Elastomers segment achieved a turnaround to profitability from an operating loss of ¥7,962 million in the previous fiscal year.

The company manufactures and sells Influenza Vaccine, rapid antigen diagnostic kits, and the Oncolytic Virus Therapy (G47Δ) in-house, recording net sales of ¥40,520 million and operating income of ¥6,247 million (15.4% margin) in the Life Innovation segment in FY2026 (ending March 2026). In March 2026, the company made clinical reagent manufacturer Kainos Laboratories a subsidiary, further strengthening its business foundation.

ENVALITH's Perspective

For FY2026 (ending March 2026), operating profit rose sharply to ¥26,225 million (up 82.0% year on year), and ordinary profit rose to ¥19,295 million (up 153.1% year on year). This substantial improvement was driven by a combination of factors: fixed cost reductions from the temporary suspension of the U.S. subsidiary, increased sales volume in Electronics & Advanced Products, and lower cost of sales (down from ¥315,655 million to ¥289,991 million). Reflecting a rebound from the large impairment loss (¥16,111 million) recorded in the previous fiscal year, profit attributable to owners of parent turned positive at ¥15,695 million. The pain of structural reforms has already been front-loaded, confirming a transition to a profit recovery phase.

The full-year forecast for FY2027 (ending March 2026) calls for net sales of ¥450,000 million (up 17.1% year on year) and operating profit of ¥30,000 million (up 14.4% year on year), a bullish outlook. However, the forecast assumptions incorporate the premise that "procurement of petroleum-derived raw materials will face disruptions during the first half, with normal conditions expected to resume from October onward" and that "raw material prices will remain elevated throughout the fiscal year," leaving external factors such as escalating tensions in the Middle East as a residual downside risk. Note that whether the earnings forecast is achieved will depend on fluctuations in the underlying assumptions (domestic naphtha price of ¥123,250/kl, exchange rate of ¥158/US$).

In FY2026 (ending March 2026), the company recorded extraordinary gains totaling ¥28,050 million, comprising a gain on sale of investment securities of ¥12,623 million, a gain on transfer of the Ofuna plant site of ¥8,188 million, and a gain on bargain purchase of ¥6,517 million (from making Toyo Styrene a consolidated subsidiary). On the other hand, extraordinary losses totaled ¥25,987 million, comprising a loss on business restructuring of ¥21,112 million (related to DPE) and a loss on step acquisition of ¥4,875 million. Given the wide swings in extraordinary gains and losses, a divergence has emerged between ordinary profit of ¥19,295 million and pre-tax profit of ¥21,357 million. The company continues to face scrutiny over improving its underlying earnings power in order to achieve the targets of Mission2030.

Growth Strategy

Accelerating specialization through concentrated investment in ICT & Energy, Healthcare, and Sustainable Living under Mission 2030

Expanding production capacity for Spherical Silica / Spherical Alumina (Fused Silica-based Fillers) to capture growing demand for AI-related semiconductors. Construction in progress has expanded to ¥78,997 million (from ¥54,942 million in the previous period), with capital investment now in full swing. For FY2027 (ending March 2027), the segment is projected to post net sales of ¥110,000 million and operating income of ¥13,000 million.

Promoting a shift away from dependence on infectious disease-related demand for POCT test reagents, while expanding adoption of Oncolytic Virus Therapy (G47Δ). In FY2026 (ending March 2026), the segment saw lower sales and profit due to the winding down of infectious disease demand, but is expected to recover to net sales of ¥45,000 million and operating income of ¥6,000 million in FY2027 (ending March 2027). Research and development activities in Germany and Singapore also continue.

Indefinitely suspended manufacturing facilities at the U.S. subsidiary Denka Performance Elastomer to reduce fixed costs. In FY2026 (ending March 2026), segment operating income improved from a loss of ¥7,962 million in the prior period to a profit of ¥68 million. For FY2027 (ending March 2027), net sales of ¥105,000 million and operating income of ¥7,000 million are projected, aiming for a full-scale contribution to earnings.

Made Toyo Styrene Co., Ltd. a consolidated subsidiary through additional share acquisition (recording a gain on negative goodwill of ¥6,517 million). Flowers Co., Ltd. and Kainos Co., Ltd. were also newly consolidated. This has strengthened the business foundation of the Polymer Solutions segment, with net sales of ¥170,000 million and operating income of ¥2,000 million projected for the segment in FY2027 (ending March 2027).

Improved asset efficiency through the transfer of the Ofuna Plant site (gain on sale of ¥8,188 million) and the sale of policy-held shares (gain on sale of ¥12,623 million). Financial soundness improved, with an equity ratio of 45.6% and an interest coverage ratio of 17.7x. The dividend is maintained at ¥100 per share annually, with the same level expected to continue in FY2027 (ending March 2027).

Last updated: July 19, 2026